News
-
-
-
PRESS RELEASE
Sandoz steps up in-house biosimilar capabilities, opening state-of-the-art development centre to capture ‘golden decade’ opportunity
Sandoz opens new biosimilar development centre in Ljubljana, Slovenia, to enhance in-house capabilities for upcoming biologic patent expiries. The state-of-the-art facility will support growth in the 'golden decade' of healthcare -
-
-
-
-
-
PRESS RELEASE
Sandoz confirms European Commission approval for biosimilars Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), strengthening position in diabetes
Sandoz Group AG confirms European Commission approval for biosimilars Bysumlog(R) (insulin lispro) and Dazparda(R) (insulin aspart), strengthening position in diabetes -
